Precocious bilateral hip joint osteoarthritis is a "form-fruste" of the arthropathy of Hereditary Haemochromatosis
University of Notre Dame Australia and Fremantle Hospital, Fremantle, Western Australia, Australia. Medical Hypotheses
(Impact Factor: 1.07).
11/2009; 74(4):719-21. DOI: 10.1016/j.mehy.2009.10.024
Osteoarthritis (OA) of the hip joint is a common disorder, especially in aging peoples of Caucasian descent. Hip OA like OA in other joints is heterogeneous and may manifest in early or late adult life. The aetiology of early onset (precocious) bilateral hip OA is poorly understood, but the clinical and radiological characteristics of this form of OA suggest that chondral resorption due to biochemical or metabolic factors is likely to be of pre-eminent importance. The hip arthropathy which occurs in Hereditary Haemochromatosis (HH) and the ostensibly idiopathic precocious bilateral concentric form of hip OA are virtually indistinguishable. Accordingly, the possibility exists that the causal factors for these conditions may be very similar. On the basis of this premise and in the light of the finding in a small observational study that HFE gene mutations are very common in precocious bilateral hip OA (100% amongst 8 sequentially collected patients), it is hypothesised that precocious bilateral hip OA is a "form-fruste" of the arthropathy of HH in which HFE gene mutation mediated articular iron deposition in hip joint tissues may be of pivotal pathogenetic importance. Confirmation of this hypothesis could have implications for the prevention and strategic medical management of this form of OA.
Available from: Hao-Li Zhang
[Show abstract] [Hide abstract]
ABSTRACT: Different kinds of highly ordered patterns of NaYF(4):Yb,Er nanoparticles on gold substrates were fabricated using a simple method combining micro-contact printing and "breath figures" techniques. Ordered arrays of water droplets were first formed in the hydrophilic regions of patterned self-assembled monolayers (SAMs). This was subsequently submerged in a chloroform solution of NaYF(4):Yb,Er nanoparticles. The particles were spontaneously assembled at the interface of chloroform/water droplet surface, leading to different kinds of uniform patterns after solvent evaporation. The structures of NaYF(4):Yb,Er particles patterns depended on the dimension of the substrate, the concentration of the NaYF(4):Yb,Er nanoparticles and the water condensation process.
Journal of Colloid and Interface Science 09/2010; 353(2):569-73. DOI:10.1016/j.jcis.2010.09.056 · 3.37 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Intervertebral disc degeneration (IDD) is regarded as an important cause of low back pain, which continues to be a common disability. IDD is thought to involve sequential changes of intervertebral disc that lead to the reduction of disc cells and the extracellular matrix. In addition, inflammation is crucially involved in IDD. Currently, there is urgent need to develop biological therapies for IDD that can both relieve symptoms and directly reverse the process of degeneration. Rhein (RH) is an anthraquinone molecule with the abilities of enhancing the synthesis of matrix components and inhibiting inflammatory response. Recently, the metabolic precursor of RH called diacerein has been demonstrated to have significant effects on pain relief and function improvement in the treatment of osteoarthritis. Given the occurrence of matrix degeneration and involvement of inflammation in IDD, we propose that RH might be a promising biological therapeutic drug for IDD due to its bioactivities. In addition, we hypothesize that the underlying mechanisms might be that RH has the ability to diminish interleukin-1 (IL-1) induced apoptosis and inhibit IL-1 induced secretion of MMPs and aggrecanases.
Medical Hypotheses 09/2011; 77(6):1105-7. DOI:10.1016/j.mehy.2011.09.013 · 1.07 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.